These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19474480)

  • 21. Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.
    Shudo E; Ribeiro RM; Perelson AS
    J Viral Hepat; 2008 May; 15(5):357-62. PubMed ID: 18380660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline.
    Layden JE; Layden TJ; Reddy KR; Levy-Drummer RS; Poulakos J; Neumann AU
    J Viral Hepat; 2002 Sep; 9(5):340-5. PubMed ID: 12225328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss.
    Dahari H; Perelson AS
    World J Gastroenterol; 2007 Jun; 13(21):3020-1. PubMed ID: 17589958
    [No Abstract]   [Full Text] [Related]  

  • 25. Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy.
    Medeiros-Filho JE; de Carvalho Mello IM; Pinho JR; Neumann AU; de Mello Malta F; da Silva LC; Carrilho FJ
    World J Gastroenterol; 2006 Dec; 12(45):7271-7. PubMed ID: 17143940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
    Pilli M; Zerbini A; Penna A; Orlandini A; Lukasiewicz E; Pawlotsky JM; Zeuzem S; Schalm SW; von Wagner M; Germanidis G; Lurie Y; Esteban JI; Haagmans BL; Hezode C; Lagging M; Negro F; Homburger Y; Neumann AU; Ferrari C; Missale G;
    Gastroenterology; 2007 Oct; 133(4):1132-43. PubMed ID: 17919489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
    Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
    J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding silibinin's modes of action against HCV using viral kinetic modeling.
    Guedj J; Dahari H; Pohl RT; Ferenci P; Perelson AS
    J Hepatol; 2012 May; 56(5):1019-1024. PubMed ID: 22245888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
    J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
    DebRoy S; Hiraga N; Imamura M; Hayes CN; Akamatsu S; Canini L; Perelson AS; Pohl RT; Persiani S; Uprichard SL; Tateno C; Dahari H; Chayama K
    J Viral Hepat; 2016 Sep; 23(9):708-17. PubMed ID: 27272497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
    Buti M; Olive G; Stalgis C; Esteban R; Guardi J
    Dig Dis Sci; 2000 Apr; 45(4):685-9. PubMed ID: 10759235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin.
    Carlsson T; Weiland O; Reichard O
    Scand J Gastroenterol; 2002 Oct; 37(10):1228-34. PubMed ID: 12408530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.
    Zeuzem S; Rodríguez-Torres M; Rajender Reddy K; Marcellin P; Diago M; Craxi A; Pockros P; Rizzetto M; Bernstein D; Shiffman ML; Lin A; Tatsch F; Hadziyannis S
    J Viral Hepat; 2012 Nov; 19(11):766-74. PubMed ID: 23043383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).
    Guedj J; Dahari H; Shudo E; Smith P; Perelson AS
    Hepatology; 2012 Apr; 55(4):1030-7. PubMed ID: 22095398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U; Aziz H; Gill ML
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
    Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
    J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
    Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
    Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.
    Enomoto M; Nishiguchi S; Kohmoto M; Tamori A; Habu D; Takeda T; Seki S; Shiomi S
    J Viral Hepat; 2004 Sep; 11(5):448-54. PubMed ID: 15357651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.